Narcisa Sonia C. Comia

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
  • Flordeluna Zapata-Mesina, Ma Rosario, +5 authors Susie L. Ponce
  • 2015
Introduction: Myelofibrosis is characterized by bone marrow fibrosis, cytopenias and extramedullary hematopoiesis. Ruxolitinib is a Janus Kinase-2 inhibitor recently approved for myelofibrosis. In the Philippines, it was made available through the compassionate use program. Methods: This is a multicentre, retrospective case series of eleven patients in the(More)
Purpose: Radotinib is a second-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) approved in Korea for chronic phase chronic myeloid leukemia (CML-CP) in patients newly diagnosed or with insufficient response to other TKIs. This study was conducted to evaluate the efficacy and safety of radotinib as first-line therapy for CML-CP.Experimental Design: This(More)
  • 1